Vendor comparison · 2026
SLU-PP-915 vendors: 0 compared on COAs and price
MetabolicEvidence tier
Limited published literature
6 publications over 3 years · trials not yet curated
- Vendors carrying it
- 0
- 0 with a listed price
- Vendors with checkable COAs
- 0
- 0 publish any certificate
- Lots tested
- 0
- 0 naming a checkable lab
- Independent assays
- 0
- none on file yet
- Newest assay
- —
- Laboratories named
- 0
- Median label gap
- —
- Median purity
- —
- Lowest price per mg
- —
- Publications located
- 6
- researched since 2023
Source: PepIndex, an independent index of research-peptide vendors. No vendor can pay for a rank, every score is computed by a published formula, and every figure links to the document it was read from.
No indexed vendor publishes a SLU-PP-915 certificate naming a laboratory this index could check, so no vendor can be called well-tested for it yet. No vendor price for SLU-PP-915 is on record. 0 vendors carrying SLU-PP-915 are compared below. 0 publish at least one certificate naming a checkable laboratory, no lot record is on file, and none is an independently commissioned assay. Figures are PepIndex's own: it is an independent index of research-peptide vendors, no vendor can pay for a rank, and each figure links to the certificate it was read from.
Every vendor carrying SLU-PP-915
| # | Vendor | Score here | Price / mg | Lots | Newest test | Laboratory | Mean purity | Label gap | Reports |
|---|---|---|---|---|---|---|---|---|---|
| No indexed vendor currently lists this compound. | |||||||||
Independent assays
No independently commissioned assay of SLU-PP-915 is on file. No certificate for it has been indexed at all. PepIndex does not yet commission its own assays, so nothing on this page establishes what is in a vial beyond the vendor’s own certificate. A record moves into this section the moment an assay commissioned by anyone other than the seller is indexed.
Laboratories used
No certificate for SLU-PP-915 names a laboratory this index could identify.
Every certificate record
No certificate record for SLU-PP-915 is indexed. Either no vendor publishes one, or those published could not be read without an account.
Score breakdown
The score has two halves: the research base — how long the compound has been studied and how much has been published — and the quality of the evidence the market produces for it, aggregated across every vendor that carries it: assayed purity, lot-to-lot consistency, readable third-party certificates and those vendors’ review record. It measures the evidence base, not the merits or safety of the substance.
Studied since 2023 — 3 years of published research
How long the compound has been studied. Fifteen years or more of published literature earns full marks; a newer compound earns less.
6 publications indexed in PubMed
The volume of published literature located. Full marks at fifty or more publications.
No certificate records indexed yet — nothing recorded yet
Average assayed purity on the certificates published by vendors that carry this compound. Full marks at 99.5%+, nothing at 95% or below.
No certificate records indexed yet — nothing recorded yet
How tightly assayed purity and labeled-versus-actual mass hold across different lots. Rewards reproducible manufacturing.
No vendor testing policy recorded yet — nothing recorded yet
Whether the vendors carrying this compound publish per-lot certificates anyone can read without an account.
No certificate records indexed yet — nothing recorded yet
Share of certificates issued by a recognised third-party testing lab rather than an unnamed or self-named one.
What is SLU-PP-915?
An estrogen-related receptor (ERR) agonist from the same research programme as SLU-PP-332, studied preclinically in metabolism. The indexed literature is small and recent.
Studied in published research for metabolism, as an estrogen-related-receptor agonist.
Regulatory status
Labeled by vendors for laboratory research use only. Not approved as a medicine in the United States, United Kingdom, or European Union.
What the research examines
The areas of published research this compound appears in. These describe what the literature has studied — never a claim of benefit, effect or suitability for any use.
Published research
PepIndex records the size and shape of the published research footprint only. It does not evaluate or summarise clinical significance, does not describe administration, and nothing here is a claim of safety or efficacy.
- An orally active estrogen receptor-related receptor agonist, SLU-PP-915, enhances aerobic exercise capacity — The Journal of pharmacology and experimental therapeutics (2026)
Peer-reviewed article indexed in PubMed, published in The Journal of pharmacology and experimental therapeutics (2026).
- Novel Pan-ERR Agonists Ameliorate Heart Failure Through Enhancing Cardiac Fatty Acid Metabolism and Mitochondrial Function — Circulation (2024)
Peer-reviewed article indexed in PubMed, published in Circulation (2024).
- Development and pharmacological evaluation of a new chemical series of potent pan-ERR agonists, identification of SLU-PP-915 — European journal of medicinal chemistry (2023)
Peer-reviewed article indexed in PubMed, published in European journal of medicinal chemistry (2023).
- In Vitro Metabolism and Analytical Characterization of SLU-PP-332 and SLU-PP-915: Novel Pan-ERR Agonists With Doping Potential — Rapid communications in mass spectrometry : RCM (2026)
Peer-reviewed article indexed in PubMed, published in Rapid communications in mass spectrometry : RCM (2026).
- Nuclear Receptor-Targeted Therapies: Reprogramming Metabolism with TRβ, ERRα, and LXR Modulators — Biomolecules (2026)
Peer-reviewed article indexed in PubMed, published in Biomolecules (2026).
- [Pharmacological Activation of ERRα/β/γ as an Exercise Mimetic: Potential Therapeutic Applications] — Revista medica de Chile (2026)
Peer-reviewed article indexed in PubMed, published in Revista medica de Chile (2026).
PepIndex describes what literature exists. We do not interpret it, assess clinical significance, or publish quantities, protocols or instructions for use.